TLR2 and asthma: A multitude of studies demonstrate that TLR2 stimulation with systemic or mucosal administration of synthetic agonists can prevent antigen presenting cells from eliciting a TH2-polarized response, thereby reducing IgE antibodies and allergenicity in murine asthma models [24–27].